NEW YORK, February 21, 2017 /PRNewswire/ --
Stock-Callers.com is closely monitoring the performances of four Biotech stocks, which are ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Clovis Oncology Inc. (NASDAQ: CLVS), Galena Biopharma Inc. (NASDAQ: GALE), and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). As per an Investopedia report last Friday, February 17th, 2017, the iShares Nasdaq Biotechnology ETF is up 10.4% year-to-date, while the SPDR S&P Biotech ETF is higher by 16.1%. You can access our complimentary research reports on these stocks now at:
San Diego, California headquartered ACADIA Pharmaceuticals Inc.'s stock finished last Friday's session 0.15% higher at $39.28. A total volume of 1.67 million shares was traded. The Company's shares have surged 24.98% in the past month, 37.58% in the previous three months, and 36.20% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 24.87% and 24.38%, respectively. Additionally, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 73.07. Visit us today and download your complete report on ACAD for free at:
On Friday, shares in Boulder, Colorado headquartered Clovis Oncology Inc. edged 7.22% higher, ending the session at $65.80. The stock recorded a trading volume of 2.94 million shares, which was higher than its three months average volume of 2.26 million shares. The Company's shares have gained 15.22% in the last one month, 88.54% in the previous three months, and 48.13% on an YTD basis. The stock is trading 27.31% above its 50-day moving average and 118.37% above its 200-day moving average. Moreover, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have an RSI of 66.22.
On February 03rd, 2017, research firm Chardan Capital Markets downgraded the Company's stock rating from 'Neutral' to 'Sell', with a target price of $36 per share.
On February 09th, 2017, Clovis Oncology announced that it will report Q4 and year-end 2016 financial results on February 22nd, 2017, after the close of the US financial markets. Clovis' senior management will host a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the Company's results in greater detail. The complimentary research report on CLVS can be accessed at:
San Ramon, California-based Galena Biopharma Inc.'s shares closed the session flat at $0.75 with a total trading volume of 1.25 million shares. The stock is trading 57.64% below its 50-day moving average. Shares of the Company, which focuses on developing and commercializing oncology therapeutics that address major unmet medical needs, have an RSI of 26.15.
On February 06th, 2017, research firm FBR & Co. downgraded the Company's stock rating from 'Outperform' to 'Market Perform' while revising its previous target price from $11 a share to $4 a share.
On February 08th, 2017, Galena Biopharma announced the pricing of an underwritten public offering of units with anticipated gross proceeds of $17,000,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galena. Each unit consists of one full share of its common stock and a warrant to purchase one share of its common stock and is priced at $1.00 per unit. The warrants are immediately exercisable at a price of $1.10 per share of common stock and will expire on the fifth anniversary of the date of issuance. Register for free on Stock-Callers.com and download the PDF research report on GALE at:
Last Friday at the close, shares in Bethesda, Maryland headquartered Northwest Biotherapeutics Inc. recorded a trading volume of 1.96 million shares, which was above their three months average volume of 1.89 million shares. The stock ended the session 7.06% lower at $0.40. The Company's shares have advanced 13.48% since the start of this year. The stock is trading below its 50-day moving average by 10.76%. Furthermore, shares of Northwest Biotherapeutics, which discovers and develops immunotherapy products to treat cancer in the US and internationally, have an RSI of 41.91.
On February 06th, 2017, Northwest Biotherapeutics provided a further update about its Phase-III trial of DCVax®-L for Glioblastoma multiforme brain cancer. The Company announced that the partial clinical hold on the trial has been lifted by the FDA, and that the trial has accumulated a sufficient number of events toward the progression-free survival endpoint, but not yet for the overall survival endpoint. The Company noted that it remains blinded to all trial data, and is only receiving and reporting updates on a blinded basis. Get free access to your research report on NWBO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA